Sorafenib in HCC. Discussion points
|
|
- Harvey Henderson
- 5 years ago
- Views:
Transcription
1 Discussion points in Andrew X. Zhu, MD, PhD 214 CASL Meeting-Consensus, Controversies and Future Directions in -data from phase III trials ptimal Dosing Side effects and management strategies use in Child-Pugh B Liver Cancer Incidence: Sixth Most Common Cancer Worldwide 1 Targets Tumor Cell Proliferation and Angiogenesis Lung 1,549,121 Breast 1,31,867 Colon/Rectal 1,167,2 Stomach 1,66,543 Prostate 782,647 Liver 711,128 Cervix Uteri 559,94 Esophagus 529,283 Leukemia 33,963 Bladder 314,256 vary 23,555 Corpus Uteri 226,787 ral Cavity 2,774 on-hodgkin's Lymphoma 196,298 2, 4, 6, 8, 1,, 1,2, 1,4, 1,6, 1,8, is the most common primary liver malignancy in adults 2 RAF MEK ERK RAS Tumor Cell HGF Mcl-1 ucleus HIF Apoptosis HGF PDGF VEGF Proliferation Survival Autocrine loop Mitochondria Endothelial Cell or Pericyte Paracrine stimulation PDGFR-b Mitochondria Apoptosis PDGF-b RAF MEK ERK ucleus RAS VEGF VEGFR-2 Angiogenesis: Differentiation Proliferation Migration Tubule formation 1. Garcia M, et al. American Cancer Society, Accessed March 2, Perz JF, et al. J Hepatol. 26;45: HGF = hepatocyte growth factor. Avila MA, et al. ncogene. 26;25: ; Liu L, et al. Cancer Res. 26;66: ; Semela D, et al. J Hepatol. 24;41:864-88; Wilhelm SM, et al. Cancer Res. 24;64: Cl CF 3 : Inhibits Serine/Threonine and Tyrosine Kinases H Serine/threonine Kinases Kinase IC 5 (nm) Raf-1 6 B-Raf 25 B-raf V6E 38 p38 38 Mnk-2 15 ERK-1, MEK- 1, PKA, PKB, PKC, cdk1/cyclinb, pim-1 H >1, Wilhelm S et al. Cancer Res. 24;64:799 19; Riedl B et al. Poster presented at AACR March 21, ew rleans, LA *Determined on mouse enzyme # Carlomagno, F. et al. J atl. Cancer Inst. 26; 98 p H CH 3 Receptor Tyrosine Kinases Kinase IC 5 (nm) VEGFR-1 26 VEGFR-2 9 VEGFR-3* 2 FLT3 33 RET # 47 PDGFR-b * 57 C-KIT 68 FGFR-1 58 c-met, IGFR-1, EGFR, HER2, LCK >1, Phase III trial of in (SHARP): study design Eligibility Advanced ECG PS 2 Child Pugh A o prior systemic therapy Stratification Macroscopic vascular invasion (portal vein) and/or extrahepatic spread ECG PS ( vs 1 2) Geographic region R A D M I S E 1:1 n=299 n=33 Primary end points: S, TTSP (assessed by FHSI-8) Secondary end points: TTP (independent assessment) sorafenib 4mg b.i.d. SHARP = Assessment Randomized Protocol ECG PS = Eastern Cooperative ncology Group Performance Status S = overall survival; TTSP = time to symptomatic progression; TTP = time to progression FHSI-8 = Functional Assessment of Cancer Therapy-Hepatobiliary Symptom Index-8 Llovet JM, et al. Engl J Med 28;359:
2 Median verall Survival, Months SHARP Phase III Trial Randomized Phase III Trial of vs in Asian With Advanced : Study Design Eligibility Advanced ECG PS -2 Child Pugh A o prior systemic therapy Stratification MVI (portal vein) and/or EHS ECG PS ( vs 1-2) Geographic region R A D M I Z E 2:1 n=15 n=76 4mg bid End points S, TTSP (FSHI8-TSP), TTP, response (RECIST), and safety o primary end point defined Cheng A, et al. J Clin ncol. 28;26. Abstract 459. Updated from oral presentation at ASC; Chicago, IL; June 28. Asia-Pacific Phase III Trial SHARP vs Asia-Pacific Study: Efficacy Endpoint S SHARP 1 Asia-Pacific 2 vs Hazard Ratio (95% CI) P Value 1.7 vs 7.9 mo.69 ( ) <.1 vs Hazard Ratio (95% CI) P Value 6.5 vs 4.2 mo.68 (.5-.93).14 TTSP 1.8 ( ) ( ).5 TTP 5.5 vs 2.8 mo.58 ( ) < vs 1.4 mo.57 ( ) <.1 RR 2% vs 1% 3.3% vs 1.3% 1. Llovet JM, et al. Engl J Med. 28;359(4): Cheng AL, et al. Lancet ncol. 29;1(1): SHARP: Exploratory Subgroup Survival Analysis Prolongs Survival in Advanced Regardless of Patient Characteristics or Extent of Disease ECG PS ECG PS 1 & 2 o extrahepatic spread Extrahepatic spread o macroscopic vascular invasion Macroscopic vascular invasion o macroscopic VI and/or extrahepatic spread Macroscopic VI and/or extrahepatic spread. Favors Favors HR (95% CI) for Survival Llovet JM, et al. Engl J Med. 28;359: Exploratory Subgroup Analyses HR =.69 (95% CI: 2 HR =.79 HR =.75 HR =.58 HR =.76 HR =.68 HR =.71 HR =.77 HR = ) P<.1 verall Prior Prior HCV 3 Alcoholic ECG ECG MVI o MVI Population 1 Curative TACE 2 n = 178 Cirrhosis 4 PS 5 PS and/or and/or n = 62 Therapy 2 n = 176 n = 159 n = 325 n = 277 EHS 6 EHS 6 n = 158 n = 421 n = Llovet JM, et al. Engl J Med. 28;359(4): Galle PR, et al. EASL Bolondi L, et al. J Clin ncol. 28;25(suppl): Abstract Craxi A, et al. J Clin ncol. 28;25(suppl): Abstract Raoul J, et al. J Clin ncol. 28;25(suppl): Abstract Sherman M, et al. J Clin ncol. 28;25(suppl): Abstract
3 SHARP: Drug-Related Adverse Events (%) (n = 299) (n = 32) Treatment-related SAEs Drug-related SAEs 13 9 Grade 8, 7, 6, 5, Alpha-Fetoprotein Trend on 78,5 Drug-Related AEs Any 3/4 Any 3/4 Diarrhea 39 8/ 11 2/ Hand-foot skin reaction 21 8/ 3 <1/ Anorexia 14 <1/ 3 <1/ Alopecia 14 / 2 / ausea 11 <1/ 8 1/ Weight loss 9 2/ <1 / Pain (abdomen) 8 2/ 3 <1/ Bleeding 7 <1/ 4 <1/<1 Vomiting 5 1/ 3 <1/ Liver dysfunction <1 <1/ / 4, 3, 2, 1, 4, 2,581 2,727 11,3 6,8 1,152 3,356 14, Llovet JM, et al. Engl J Med. 28;359(4): Dosing Standard dose schedule: 4 mg bid Lack of prospective randomized trials to assess lower dose in comparison with standard dose Dose escalation scheme can be considered and often used in practice in patients with borderline PS and compromised hepatic function: start at 4 mg daily and increase as tolerated Hand-Foot Skin Reaction Hand-foot skin reaction is a group of symptoms affecting the hands and/or feet 1,2 Varying degrees of severity that tend to decrease during the course of therapy Side effects of anti-angiogenic therapies usually occur during the first few weeks of treatment 3 may require 2,3 : Topical treatments Temporary suspension of treatment or dose reduction until the episode resolves Permanent dose reduction (in severe or persistent cases) Grade 1 Incidence: 8%* *Incidence reported from the SHARP trial.[4] Grade 2 Incidence: 6%* Grade 3 Incidence: 8%* 1. Moldawer, Figlin R. ncol urs Forum.28;4:699-78; 2. Wood LS. Commun ncol. 26;3:558-62; 3. Alexandrescu DT, et al. Clin Exp Dermatol. 27;32:71-4; Photos courtesy of Elizabeth Manchen, R, MS, C. Management of Hand-Foot Skin Reaction Early intervention may prevent progression of symptoms and avoid treatment interruption or dose reduction 1 are advised to 1,2,3 : Wear comfortable soft-soled footwear (eg, gel insoles) Apply hydrating cream, preferably containing urea Bathe regularly in lukewarm water containing Epsom salts (magnesium sulphate) If possible, patients should consult a podiatrist before starting treatment 1. Wood LS. Commun ncol. 26;3:558-62; 2. Anderson R, et al. ncologist. 29; ; 3. Robert C, et al. Lancet ncol. 25;6: Fatigue ot always attributable to drug therapy Usually managed by educating the patient Advise patients to: Stay as active as possible because that will help them sleep better Maintain normal work and social schedules Take breaks as needed Tell their doctor or nurse if they cannot tolerate activity or if their fatigue worsens Wood LS. Commun ncol. 26;3:
4 Geometric mean plasma concentration (mg/l) AUC -12 /Dose (mg x h/l/mg) C max/dose (mg/l/mg) ptimizing the Management of AEs With Phase I Study of in Japanese With : Pharmacokinetics in patients with Child Pugh A and B Most AEs related to sorafenib are predictable and manageable Preventive measures can be taken to avoid dose reductions or treatment interruptions Treatment rarely needs to be permanently discontinued Good communication is vital among patients, clinicians, and nurses Advanced Solid Tumor (CP A) (CP B) Advanced Solid Tumor (CP A) (CP B) Furuse J, et al. Cancer Sci. 28;99: Phase II trial in Child Pugh A and B patients: plasma concentrations of in Child Pugh B 1 8 Child Pugh A Child Pugh B Time (hours) Abou-Alfa GK, et al. J Clin ncol 26;24: Abou-Alfa GK, et al. ASC 28, Chicago, IL, USA Phase II trial: safety by Child Pugh class C P A (%) (n=98) C P B (%) (n=38) AEs SAEs Fatigue HFSR 3 13 Diarrhoea Bilirubin increase 18 4* Ascites Encephalopathy 2 11 Length of therapy 24.9 weeks 12.9 weeks Dose reductions 31% 21% *Due to cirrhosis not associated with liver failure or an increase in liver enzymes SAEs = serious AEs Abou-Alfa GK, et al. J Clin ncol 26;24: Measure GIDE Study Marrero JA, et al. J Clin ncol. 211;29(suppl): Abstract 41. Child A (%) n = 965 (61%) Child B (%) n = 368 (23%) 8-mg starting dose, n (%) 738 (76) 261 (71%) Daily dose (median, mg) Treatment duration (median, weeks) discontinued due to AEs, n (%) (23) 139 (38) 4
5 safety in patients with mild to moderate liver impairment exposure values were comparable with those in patients without liver impairment o dose adjustment for sorafenib is required in patients with Child Pugh A or B status can be safely given in Child-Pugh B patients but have more frequent worsening of their liver cirrhosis and worse survival Lack of prospective randomized trials to assess the efficacy/safety in Child B patients-ongoing Italian randomized phase III trial Lessons From Development It has modest efficacy in advanced with Child A cirrhosis Toxicity management and dose adjustment is critical for clinical benefits utcomes vary depending on the etiology, geographic regions, and severity of underlying cirrhosis o validated predictive biomarkers for sorafenib in SEARCH: Study bjective and Design bjective To compare the efficacy and safety of sorafenib plus erlotinib with sorafenib plus placebo as first-line treatment in patients with advanced/unresectable Design Randomized, double-blind, placebo-controlled phase III trial conducted in 26 countries in Europe, orth and South America, and Asia Pacific Study aim: show a 33% increase in median S compared to sorafenib + placebo using a one-sided alpha of.25; a total of 521 events are required to achieve 9% power verall Survival* HR: % Cl:.781, 1.16 P =.24 (1-sided) + Erlotinib Median: 9.5 mo + Median: 8.5 mo *ITT Population Zhu AX, et al. Ann ncol. 212;23(suppl 9): Abstract Zhu AX, et al. Ann ncol. 212;23(suppl 9): Abstract Phase II Trial of Doxorubicin ± in : Study Design Clinical utcomes Eligibility Advanced ECG PS -2 Child Pugh A o prior systemic therapy o prior chemoembolization o history of organ allograft Primary objective TTP Secondary objectives RR, PFS, S, safety R A D M I Z E 1:1 n=47 n=49 Period 1 Period 2* Doxorubicin 6mg/m 2 + sorafenib 4mg bid q3w Doxorubicin 6mg/m 2 + placebo q3w 4mg bid Inhibition of the Ras/Raf/MEK/ERK pathway may prevent activation of the multidrug resistance pathway * or placebo continued until withdrawal, PD, or death in Period 2. q3w = once every 3 weeks. Abou-Alfa GK, et al. JAMA 21 TTP 6.4 vs 2.8 months; S 13.7 vs 6.5 months, and PFS 6. vs 2.7 months 5
6 Conclusions is first line therapy for patients with advanced due to portal vein invasion (PVI) or metastatic disease (BCLC stage C) or in patients who have progressed after TACE (BCLC stage B) [Level 1B]. should only be used in patients with preserved liver function (Child Pugh A) [Level 1B] with compromised PS and hepatic function should be considered for lower starting dose of sorafenib (Level 2B) Toxicity management and dose adjustment is critical for clinical benefits ovel agents and strategies are desperately needed 6
Nexavar in advanced HCC: a paradigm shift in clinical practice
Nexavar in advanced HCC: a paradigm shift in clinical practice Tim Greten Hanover Medical School, Germany Histopathological progression and molecular features of HCC Chronic liver disease Liver cirrhosis
More information蕾莎瓦 Nexavar 臨床試驗資料 (HCC 肝細胞癌 )
蕾莎瓦 Nexavar 臨床試驗資料 (HCC 肝細胞癌 ) 1 Sorafenib Improves Survival in Hepatocellular Carcinoma: Results of a Phase III Randomized, -Controlled Trial Josep M. Llovet, Sergio Ricci, Vincenzo Mazzaferro, Philip
More informationHCC: Epidemiology. Update on treatment of advanced hepatocellular carcinoma. Incidence of HCC is increasing
Update on treatment of advanced hepatocellular carcinoma Jean-Luc Raoul Centre E Marquis Rennes, Brittany France HCC: Epidemiology Europe - USA: C virus, alcohol obesity, iron Europe: 4 deaths / year 6
More informationManagement of side-effects of anti-angiogenetic inhibitors in treating HCC
Management of side-effects of anti-angiogenetic inhibitors in treating HCC Massimo Di Maio Clinical Trials Unit National Cancer Institute, Napoli dimaiomax@libero.it BCLC staging system and treatment strategy
More informationCisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer. Valle J et al. N Engl J Med 2010;362(14):
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer Valle J et al. N Engl J Med 2010;362(14):1273-81. Introduction > Biliary tract cancers (BTC: cholangiocarcinoma, gall bladder cancer,
More informationCurrent Concepts in the Treatment of HCC
Falk Symposium 167 Current Concepts in the Treatment of HCC Peter R. Galle I. Medical Department Johannes Gutenberg-University Mainz Germany Liver cancer: sixth most common cancer worldwide Most common
More information12 AISF Special Conference Sorafenib: magnitude of benefit, side effects and stopping rules 9 years after approval
12 AISF Special Conference Sorafenib: magnitude of benefit, side effects and stopping rules 9 years after approval ARMANDO SANTORO Roma 10-6-2016 SORAFENIB APPROVAL 29 OCTOBER 2007 Marketing authorization
More informationIl treatment plan nella terapia sistemica dell epatocarcinoma
Il treatment plan nella terapia sistemica dell epatocarcinoma M. Iavarone, MD PhD CRC A.M. e A. Migliavacca Center for the Study of Liver Disease Division of Gastroenterology and Hepatology Fondazione
More informationThe Current Champion: Angiogenesis inhibitors
The Current Champion: Angiogenesis inhibitors Baek-Yeol RYOO University of Ulsan College of Medicine ASAN Medical Center Dept. of Oncology Seoul, Korea Survival probability Sorafenib: Overall Survival
More informationRiunione Monotematica A.I.S.F The future of liver diseases. HEPATIC NEOPLASMS The challenge for new drugs
Riunione Monotematica A.I.S.F. 2016 The future of liver diseases Milan 13 th -15 th October 2016 Centro Congressi Fondazione Cariplo HEPATIC NEOPLASMS The challenge for new drugs Massimo Iavarone Gastroenterology
More informationHepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary)
Hepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary) Staff Reviewers: Dr. Yoo Joung Ko (Medical Oncologist, Sunnybrook Odette Cancer
More informationAdvances in Systemic Therapy Hepatocellular Carcinoma (HCC) Dr ZEE Ying Kiat HASLD Conference Ho Chi Minh City, 18 December 2016
Advances in Systemic Therapy for Hepatocellular Carcinoma (HCC) Dr ZEE Ying Kiat HASLD Conference Ho Chi Minh City, 18 December 2016 Scope Background Staging and treatment strategies Current systemic therapy
More informationΗπατοκυτταρικός Καρκίνος Συστηματική Θεραπεία. Θωμάς Μακατσώρης Επίκ. Καθ. Παθολογίας-Ογκολογίας Ιατρική Σχολή Πανεπιστημίου Πατρών 11/5/2018
Ηπατοκυτταρικός Καρκίνος Συστηματική Θεραπεία Θωμάς Μακατσώρης Επίκ. Καθ. Παθολογίας-Ογκολογίας Ιατρική Σχολή Πανεπιστημίου Πατρών 11/5/2018 Advisory Board Disclosures Roche, Boeringer, Sanofi, Astra Zeneca,
More informationNovel Molecular Molecular Therapies In Hepatocarcinoma Prof Eric
Novel Molecular Therapies In Hepatocarcinoma Prof. Eric Raymond Department of Médical Oncology Hôpital Beaujon, Clichy Université Paris 7 Denis Diderot INSERM-U728 eric.raymond@bjn.aphp.fr HCC is a highly
More informationA) PUBLIC HEALTH B) PRESENTATION & DIAGNOSIS
Hepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary), April 2017 by Dr. Jenny Ko (Medical Oncologist, Abbotsford Centre, BC Cancer
More informationUPDATE TO THE MANAGEMENT OF PATIENTS WITH HCC HCA
UPDATE TO THE MANAGEMENT OF PATIENTS WITH HCC HUSSEIN K. MOHAMED MD, FACS. Transplant and Hepato-biliary Surgery Largo Medical Center HCA DISCLOSURE I have no financial relationship(s) relevant to the
More informationTREATMENT ALGORITHM FOR HEPATOCELLULAR CARCINOMA
HCC treatment : A permanent challenge! TREATMENT ALGORITHM FOR HEPATOCELLULAR CARCINOMA Michel Ducreux, MD, PhD Paul Brousse University Hospital Gustave Roussy Institute Villejuif, FRANCE A low level of
More informationHCC with Intrahepatic Portal vein Tumour Should Be Treated by Systemic Therapy Rather Than Transarterial Therapy (Pros)
HCC with Intrahepatic Portal vein Tumour Should Be Treated by Systemic Therapy Rather Than Transarterial Therapy (Pros) Yi-Hsiang Huang, MD, Ph.D. Professor, Division of Gastroenterology & Hepatology,
More informationStudy Objective and Design
Randomized, Open Label, Multicenter, Phase II Trial of Transcatheter Arterial Chemoembolization (TACE) Therapy in Combination with Sorafenib as Compared With TACE Alone in Patients with Hepatocellular
More informationSorafenib for Advanced Hepatocellular Carcinoma
CED-SOS Advice Report 7 ARCHIVED 2012 Sorafenib for Advanced Hepatocellular Carcinoma J. Knox, R. Cosby, K. Chan, and M. Sherman A Quality Initiative of the Program in Evidence-Based Care (PEBC), Cancer
More informationAngiogenesis and tumor growth
Anti-angiogenic agents: where we are? Martin Reck Department of Thoracic Oncology Hospital Grosshansdorf Germany Angiogenesis and tumor growth Journal of experimental Medicine 1972; 133: 275-88 1 Angiogenesis
More informationNew Therapies in HCC Bruno Sangro Clínica Universidad de Navarra. IdISNA. CIBERehd. Pamplona, Spain
New Therapies in HCC Bruno Sangro Clínica Universidad de Navarra. IdISNA. CIBERehd. Pamplona, Spain PHC 2018 - www.aphc.info EASL-EORTC Guidelines EASL EORTC Guidelines. J Hepatol. 2012;56:908-43. Systemic
More informationNew Insights: Systemic Therapy for Advanced Hepatocellular Carcinoma (HCC)
New Insights: Systemic Therapy for Advanced Hepatocellular Carcinoma (HCC) Thomas W.T. Leung Associate Director and Honorary Consultant Comprehensive Oncology Centre Hong Kong Sanatorium and Hospital Hong
More informationQUANDO LA TERAPIA MEDICA
IL NODULO EATICO dalla diagnosi.. alla terapia Sala Conferenze, Biblioteca "Rosanna Benzi" Genova Voltri 21 Settembre 2013 QUANDO LA TERAIA MEDICA Dott. Gianfranco ercario U.O.S. di Gastroenterologia OEI
More informationThe Management of Advanced Stage Hepatocellular Carcinoma
The Management of Advanced Stage Hepatocellular Carcinoma Pierce K.H Chow MD PhD Professor, Duke-NUS Graduate Medical School Singapore Senior Consultant Surgeon, National Cancer Center Singapore Senior
More informationPaul Martin MD FACG. University of Miami
Paul Martin MD FACG University of Miami 1 Liver cirrhosis of any cause Chronic C o c hepatitis epat t s B Risk increases with Male gender Age Diabetes Smoking ~5% increase in HCV-related HCC between 1991-28
More informationAddictive Benefit of Transarterial Chemoembolization and Sorafenib in Treating Advanced Stage Hepatocelluar Carcinoma: Propensity Analysis
Addictive Benefit of Transarterial Chemoembolization and Sorafenib in Treating Advanced Stage Hepatocelluar Carcinoma: Propensity Analysis Gwang Hyeon Choi, Ju Hyun Shim*, Min-Joo Kim, Min-Hee Ryu, Baek-Yeol
More informationAdvances in percutaneous ablation and systemic therapies for hepatocellular carcinoma
Advances in percutaneous ablation and systemic therapies for hepatocellular carcinoma Paris Hepatology Congress 2019 Pierre Nahon Service d Hépatologie Hôpital Jean Verdier Bondy Université Paris 13 INSERM
More informationFirst-line therapy for unresectable HCC:
ESMO GI Cancer Preceptorship 15 November 2017 Singapore First-line therapy for unresectable HCC: an oncologist s viewpoint Chiun Hsu, MD, PhD G raduate I n stitute of Oncology, National Taiwan Univers
More informationAngiogenesis Targeted Therapies in Renal Cell Carcinoma
Angiogenesis Targeted Therapies in Renal Cell Carcinoma John S. Lam, MD Department of Urology David Geffen School of Medicine University of California-Los Angeles Patient Case CC: Abdominal pain VS: T
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationDrug Discovery Platform: Cancer Cell Signaling. MET Inhibitor. Merestinib, LY Christensen JG, et al1; Eder JP, et al 2
MET Inhibitor Drug Discovery Platform: Cancer Cell Signaling Christensen JG, et al1; Eder JP, et al 2 A Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo Plus and Gemcitabine
More informationHepatocellular Carcinoma: A major global health problem. David L. Wood, MD Interventional Radiology Banner Good Samaritan Medical Center
Hepatocellular Carcinoma: A major global health problem David L. Wood, MD Interventional Radiology Banner Good Samaritan Medical Center Hepatocellular Carcinoma WORLDWIDE The #2 Cancer Killer Overall cancer
More informationWhen patients fail on molecular targeted therapy: what to do in 2013
When patients fail on molecular targeted therapy: what to do in 2013 For 3 rd APASAL HCC conference on 23 Nov 2013 Dr. Stephen L. Chan Department of Clinical Oncology The Chinese University of Hong Kong
More informationCarcinoma de Tiroide: Teràpies Diana
Carcinoma de Tiroide: Teràpies Diana Jaume Capdevila, MD GI and Endocrine Tumor Unit Vall d Hebron University Hospital Developmental Therapeutics Unit Vall d Hebron Institute of Oncology THYROID CANCER:
More informationManagement of advanced Hepatocellular carcinoma
Management of advanced Hepatocellular carcinoma V Di Martino* Acknowledgements to T Thevenot *Advisory board/lectures/travel facilities: Case report (1) Mr T. Philippe 55 yrs old Past IV drug user (1985)
More informationHepatocellular Carcinoma
Hepatocellular Carcinoma Ghassan K. Abou-Alfa Memorial Sloan Kettering Cancer Center Great Debates & Updates in GI Malignancies New York, NY March 28, 2015 Epidemiology Scoring and staging Agenda Curative
More informationTivantinib Overview April 2016
Tivantinib Overview April 2016 Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act with
More informationObservational registry of sorafenib use in clinical practice across. Child-Pugh subgroups: The GIDEON study
Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study Jorge A. Marrero, Masatoshi Kudo, Alan P. Venook, Sheng-Long Ye, Jean-Pierre Bronowicki, Xiao-Ping
More informationLiver resection for HCC
8 th LIVER INTEREST GROUP Annual Meeting Cape Town 2017 Liver resection for HCC Jose Ramos University of the Witwatersrand Donald Gordon Medical Centre The liver is almost unique in that treatment of the
More informationMET Inhibitor. Merestinib, LY Drug Discovery Platform: Cancer Cell Signaling. Derived from Christensen JG, et al 1 ; Eder JP, et al.
MET Inhibitor Merestinib, LY2801653 Derived from Christensen JG, et al 1 ; Eder JP, et al. 2 Drug Discovery Platform: Cancer Cell Signaling A Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib
More informationUpdate on the Management of HER2+ Breast Cancer. Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany
Update on the Management of HER2+ Breast Cancer Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany Outline Treatment strategies for HER2-positive metastatic breast cancer since First
More information3/22/2017. I will be discussing off label/investigational use of tivantinib for hepatocellular carcinoma.
Grant/Research Support - AbbVie, Conatus, Hologic, Intercept, Genfit, Gilead, Mallinckrodt, Merck, Salix, Shire, Vital Therapies Consultant AbbVie, Gilead, Merck Member, Scientific Advisory Board Vital
More informationSurveillance for Hepatocellular Carcinoma
Surveillance for Hepatocellular Carcinoma Marion G. Peters, MD John V. Carbone, MD, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California San Francisco Recorded on April
More informationAn Update on Hepatocellular Carcinoma. Ed Gane NZ Liver Transplant Unit
An Update on Hepatocellular Carcinoma Ed Gane NZ Liver Transplant Unit Hepatocellular Carcinoma has a High Burden of Disease APSCVIR March 2018 Lung Liver Colon/Rectal Stomach Breast Cervix Uteri Esophagus
More informationVirtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer.
Virtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer Reference Slides ALK Rearrangement in NSCLC ALK (anaplastic lymphoma kinase) is a receptor
More informationLiver and Biliary Tract Cancers Critical Review
Liver and Biliary Tract Cancers Critical Review Lorenza Rimassa Oncologia Medica e Ematologia Humanitas Cancer Center Humanitas Research Hospital Rozzano (Milano) Critical review Oral presentations Melero
More informationCelsion Symposium New Paradigms in HCC Staging: HKLC vs. BCLC Staging
Celsion Symposium New Paradigms in HCC Staging: HKLC vs. BCLC Staging Ronnie T.P. Poon, MBBS, MS, PhD Chair Professor of Hepatobiliary and Pancreatic Surgery Chief of Hepatobiliary and Pancreatic Surgery
More informationManagement of HepatoCellular Carcinoma
9th Symposium GIC St Louis - 2010 Management of HepatoCellular Carcinoma Overview Pierre A. Clavien, MD, PhD Department of Surgery University Hospital Zurich Zurich, Switzerland Hepatocellular carcinoma
More informationEdith A. Perez, Ahmad Awada, Joyce O Shaughnessy, Hope Rugo, Chris Twelves, Seock-Ah Im, Carol Zhao, Ute Hoch, Alison L. Hannah, Javier Cortes
BEACON: A Phase 3 Open-label, Randomized, Multicenter Study of Etirinotecan Pegol (EP) versus Treatment of Physician s Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously
More informationAntiangiogenic Agents in NSCLC Where are we? Which biomarkers? VEGF Is the Only Angiogenic Factor Present Throughout the Tumor Life Cycle
Antiangiogenic Agents in NSCLC Where are we? Which biomarkers? Martin Reck Department e t of Thoracic c Oncology ogy Hospital Grosshansdorf Germany VEGF Is the Only Angiogenic Factor Present Throughout
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced
More informationLenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine [ID1059]
Contains AIC Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine [ID1059] Multiple Technology Appraisal Background and Clinical Effectiveness Lead team: Femi Oyebode
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationBenefit-Risk Summary of Regorafenib for the Treatment of Patients with Advanced Hepatocellular Carcinoma That Has Progressed on Sorafenib
Regulatory Issues: FDA Benefit-Risk Summary of Regorafenib for the Treatment of Patients with Advanced Hepatocellular Carcinoma That Has Progressed on Sorafenib LORRAINE PELOSOF, STEVEN LEMERY, SANDRA
More informationNintedanib in Oncology Backgrounder
For media outside the US, UK and Canada only Nintedanib in Oncology Backgrounder 1. What is nintedanib? 2. How does nintedanib work? 3. Data overview 4. Additional clinical data 5. Nintedanib approval
More informationSystemic Targeted Therapy Beyond Sorafenib
REVIEW REVIEW Systemic Targeted Therapy Beyond Sorafenib Roniel Cabrera, M.D., M.S. The quest for medical treatments for patients with advanced stage hepatocellular carcinoma (HCC) has met repeated road
More informationStudy No Title : Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationSorafenib for Egyptian patients with advanced hepatocellular carcinoma; single center experience
Journal of the Egyptian National Cancer Institute (2014) 26, 9 13 Cairo University Journal of the Egyptian National Cancer Institute www.nci.cu.adu.eg www.sciencedirect.com Original article Sorafenib for
More informationWelcome to Master Class for Oncologists. Miami, FL. December 19, The following relationships exist related to this presentation: Session 2
Session 2 Welcome to Master Class for Oncologists 8:15 AM 9:00 AM Miami, FL December 19, 2009 Alan P. Venook, MD Professor of Clinical Medicine University of California San Francisco Medical School Chief,
More informationImmune Checkpoint Inhibitors for Lung Cancer William N. William Jr.
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More information2 nd line Therapy and Beyond NSCLC. Alan Sandler, M.D. Oregon Health & Science University
2 nd line Therapy and Beyond NSCLC Alan Sandler, M.D. Oregon Health & Science University Treatment options for advanced or metastatic (stage IIIb/IV) NSCLC Suitable for chemotherapy Diagnosis Unsuitable/unwilling
More informationDo You Think Like the Experts? Refining the Management of Advanced NSCLC With ALK Rearrangement. Reference Slides Introduction
Do You Think Like the Experts? Refining the Management of Advanced NSCLC With ALK Rearrangement Reference Slides Introduction EML4-ALK Fusion Oncogene Key Driver in 3% to 7% NSCLC Inversion or Translocation
More informationAntiviral Therapy and Liver Cancer
Antiviral Therapy and Liver Cancer St. Petersburg, 070613 Markus Peck-Radosavljevic Gastroenterologie & Hepatologie AKH & Medizinische Universität Wien HCC Study Group Medizinische Universität Wien Prevention
More information6/16/2016. Treating Hepatocellular Carcinoma: Deciphering the Clinical Data. Liver Regeneration. Liver Regeneration
Treating : Deciphering the Clinical Data Derek DuBay, MD Associate Professor of Surgery Director of Liver Transplant Liver Transplant and Hepatobiliary Surgery UAB Department of Surgery Liver Regeneration
More informationHepatocellular Carcinoma. Markus Heim Basel
Hepatocellular Carcinoma Markus Heim Basel Outline 1. Epidemiology 2. Surveillance 3. (Diagnosis) 4. Staging 5. Treatment Epidemiology of HCC Worldwide, liver cancer is the sixth most common cancer (749
More informationTargeted Therapies in Gastric Cancer : Where Do We Stand Today. Yoon-Koo Kang Asan Medical Center, University of Ulsan Seoul, Korea
Targeted Therapies in Gastric Cancer : Where Do We Stand Today Yoon-Koo Kang Asan Medical Center, University of Ulsan Seoul, Korea Chemotherapy is the standard of care in advanced gastric cancer Median
More informationNews Release. Embargoed until 1:45 p.m. ET, Sunday, October 28, 2012
News Release Embargoed until 1:45 p.m. ET, Sunday, October 28, 2012 Contact: Michelle Kirkwood 703-286-1600 michellek@astro.org Concurrent use of sorafenib and stereotactic body radiotherapy for advanced
More informationA New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
Published online: March 9, 2017 Editorial A New Era of Systemic Therapy for Hepatocellular Carcinoma with Prof. M. Kudo Editor Liver Cancer Introduction The SHARP study in 2007 [1] and the Asia Pacific
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationHCC: Is it an oncological disease? - No
June 13-15, 2013 Berlin, Germany Prof. Oren Shibolet Head of the Liver Unit, Department of Gastroenterology Tel-Aviv Sourasky Medical Center and Tel-Aviv University HCC: Is it an oncological disease? -
More informationRecent advances in the management of metastatic breast cancer in older adults
Recent advances in the management of metastatic breast cancer in older adults Laura Biganzoli Medical Oncology Dept New Hospital of Prato Istituto Toscano Tumori Italy Important recent advances in the
More informationSorafenib for the treatment of advanced hepatocellular carcinoma
DOI: 10.3310/hta14suppl1/03 Health Technology Assessment 2010; Vol. 14: Suppl. 1 Sorafenib for the treatment of advanced hepatocellular carcinoma M Connock, 1 J Round, 2 S Bayliss, 1 S Tubeuf, 2 W Greenheld
More informationBackground. Capdevila J, et al. Ann Oncol. 2018;29(Suppl 8): Abstract 1307O. 1. Dasari A, et al. JAMA Oncol. 2017;3(10):
Efficacy of Lenvatinib in Patients With Advanced Pancreatic (pannets) and Gastrointestinal (ginets) WHO Grade 1/2 (G1/G2) Neuroendocrine Tumors: Results of the International Phase II TALENT Trial (GETNE
More informationRandomized Controlled Phase 2 Trial (RCT) ARQ
Tivantinib in Pretreated Hepatocellular Carcinoma (HCC): Tumor and Plasma Biomarker Analysis from the Randomized Controlled Phase 2 Trial (RCT) ARQ 197-215 L Rimassa, G Abbadessa, N Personeni, C Porta,
More informationChemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC)
Chemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC) Jeffrey Crawford, MD George Barth Geller Professor for Research in Cancer Co-Program Leader, Solid Tumor Therapeutics Program
More informationMETRIC Study Key Eligibility Criteria
The METRIC Study METRIC Study Key Eligibility Criteria The pivotal METRIC Study is evaluating glembatumumab vedotin in patients with gpnmb overexpressing metastatic triple-negative breast cancer (TNBC).
More informationOptimal management of HCC: in Asia
Optimal management of HCC: in Asia Kwang-Hyub Han, MD Department of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea Newly diagnosed HCC : > 70% occur
More informationHepatocellular Carcinoma (HCC): Who Should be Screened and How Do We Treat? Tom Vorpahl MSN, RN, ACNP-BC
Hepatocellular Carcinoma (HCC): Who Should be Screened and How Do We Treat? Tom Vorpahl MSN, RN, ACNP-BC Objectives Identify patient risk factors for hepatocellular carcinoma (HCC) Describe strategies
More informationImmunoconjugates in Both the Adjuvant and Metastatic Setting
Immunoconjugates in Both the Adjuvant and Metastatic Setting Mark Pegram, M.D. Director, Stanford Breast Oncology Program Co-Director, Molecular Therapeutics Program Trastuzumab Treatment of Breast Tumor
More informationCurrent Standards of Care of Hepatocellular Carcinoma? Prof. Mohsen Mokhtar M.D Cairo Univ.
Current Standards of Care of Hepatocellular Carcinoma? Prof. Mohsen Mokhtar M.D Cairo Univ. Disclosures Honoraria Received : Amgen, Astra Zeneca, Bohrengier, Hikma,Hospira, GSK, Lilly, Merck, MSD, Novartis,
More informationJon Trent, MD, PhD. Associate Professor Dept. of Sarcoma Medical Oncology The University of Texas, M. D. Anderson Cancer Center
Gastrointestinal Stromal Tumor GISTS 2010: After Standard of Care Jon Trent, MD, PhD Associate Professor Dept. of Sarcoma Medical Oncology The University of Texas, M. D. Anderson Cancer Center jtrent@mdanderson.org
More informationMolecular Biology of Hepatocellular Carcinoma and Targeted Therapies
Molecular Biology of Hepatocellular Carcinoma and Targeted Therapies First International Course on Translational Hepatology: Focus on HCV Disease March 9-11, 2011 Melanie B. Thomas, M.D. Associate Director
More informationDavid N. Robinson, MD
David N. Robinson, MD Background and Treatment of mrcc Background ~ 64,770 new cases of kidney/renal pelvis cancers will be diagnosed in the US in 2012 with an estimated 13,570 deaths [1] ~ 75% are clear-cell
More information17/01/2017. Use of kinase inhibitors in oncology practice. Multikinase inhibitors. Sunitinib (Sutent )targets. Many more sunitinib kinase targets (42)
Multikinase inhibitors Use of kinase inhibitors in oncology practice Prof Jacques De Grève, UZ Brussel Inhibit multiple intracellular and cell surface kinases Tyrosine or serine-threonine kinases Multitargeting
More informationHepatozelluläres Karzinom und Cholangiokarzinom was kommt nach Sorafenib? Stefan Kubicka
Hepatozelluläres Karzinom und Cholangiokarzinom was kommt nach Sorafenib? Stefan Kubicka SHARP 1 versus Asia-Pacific-Study 2 SHARP S:299/P:303 Asia-Pacific S:150/P:76 End point HR p-value HR p-value OS
More informationE2804 The BeST Trial
E2804 The BeST Trial A randomized Phase II Study of VEGF, RAF Kinase and MTOR Combination Targeted Therapy with Bevacizumab, Sorafenib and Temsirolimus in Advanced Renal Cell Carcinoma Investigators Keith
More informationEditorial on combination treatment beyond sorafenib alone for hepatocellular carcinoma with portal vein tumor thrombosis
Editorial Editorial on combination treatment beyond sorafenib alone for hepatocellular carcinoma with portal vein tumor thrombosis Sun Hyun Bae 1, Hee Chul Park 2,3 1 Department of Radiation Oncology,
More informationWHAT IS THE BEST APPROACH FOR TRANS-ARTERIAL THERAPY IN HCC?
WHAT IS THE BEST APPROACH FOR TRANS-ARTERIAL THERAPY IN HCC? Dr. Alexander Kim Chief, Vascular and Interventional Radiology, Medstar Georgetown University Hospital, USA DISCLAIMER Please note: The views
More informationSynopsis (C1034T02) CNTO 95 Module 5.3 Clinical Study Report C1034T02
Module 5.3 Protocol: EudraCT No.: 2004-002130-18 Title of the study: A Phase 1/2, Multi-Center, Blinded, Randomized, Controlled Study of the Safety and Efficacy of the Human Monoclonal Antibody to Human
More informationAn Open-Label Phase Ib/II Study of Sulfatinib in Patients with Advanced Neuroendocrine Tumors (NCT )
An Open-Label Phase Ib/II Study of Sulfatinib in Patients with Advanced Neuroendocrine Tumors (NCT02267967) J.M. Xu a, J. Li b, C.M. Bai c, N. Xu d, Z.W. Zhou e, Z.P. Li f, C.C. Zhou g, W. Wang h, J. Li
More information9th Paris Hepatitis Conference
9th Paris Hepatitis Conference Paris, 12 January 2016 Treatment of hepatocellular carcinoma: beyond international guidelines Massimo Colombo Chairman Department of Liver, Kidney, Lung and Bone Marrow Units
More informationAntiangiogenic therapy in GI cancer: current status and future directions
Riccardo Giampieri, MD, PhD Università Politecnica delle Marche Ospedali Riuniti diancona Antiangiogenic therapy in GI cancer: current status and future directions Before starting Summary - Antiangiogenesis
More informationCancer Cell Research 14 (2017)
Available at http:// www.cancercellresearch.org ISSN 2161-2609 Efficacy and safety of bevacizumab for patients with advanced non-small cell lung cancer Ping Xu, Hongmei Li*, Xiaoyan Zhang Department of
More informationPrimary Endpoint The primary endpoint is overall survival, measured as the time in weeks from randomization to date of death due to any cause.
CASE STUDY Randomized, Double-Blind, Phase III Trial of NES-822 plus AMO-1002 vs. AMO-1002 alone as first-line therapy in patients with advanced pancreatic cancer This is a multicenter, randomized Phase
More informationGASTRIC & PANCREATIC CANCER
GASTRIC & PANCREATIC CANCER ASCO HIGHLIGHTS 2005 Fadi Sami Farhat, MD Head of Hematology Oncology Division Hammoud Hospital University Medical Center Saida Lebanon Tel: +961 3 753 155 E-Mail: drfadi@drfadi.org
More informationReal-Life Experience of Sorafenib Treatment for Hepatocellular Carcinoma in Korea: From GIDEON Data
pissn 1598-2998, eissn 2005-9256 Cancer Res Treat. 2016;48(4):1243-1252 Original Article http://dx.doi.org/10.4143/crt.2015.278 Open Access Real-Life Experience of Sorafenib Treatment for Hepatocellular
More informationGastric cancer and lung cancer impose a substantial
Cyramza (Ramucirumab) Approved for the Treatment of Advanced Gastric Cancer and Metastatic Non Small-Cell Lung Cancer By Loretta Fala, Medical Writer Gastric cancer and lung cancer impose a substantial
More information